Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate effects of repeated doses of elagolix on the pharmacokinetics of omeprazole (OME), as a CYP2C19 substrate, and its metabolites in healthy premenopausal female subjects

Next Previous
Trial Profile

To evaluate effects of repeated doses of elagolix on the pharmacokinetics of omeprazole (OME), as a CYP2C19 substrate, and its metabolites in healthy premenopausal female subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elagolix (Primary) ; Omeprazole
  • Indications Endometriosis; Menorrhagia; Pain; Polycystic ovary syndrome; Uterine leiomyoma
  • Focus Pharmacokinetics

Most Recent Events

  • 22 Mar 2021 Results published in the Clinical Pharmacokinetics.
  • 06 May 2020 New trial record
  • 21 Mar 2020 Results presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top